Hints and tips:
Related Special Reports
...Since the third quarter of 2023 when it had 82 new drugs in development, the company has jettisoned 16 drugs and added 12 others, including the weight-loss drug it gained through its $3.1bn acquisition of...
...The company repeated its guidance of double-digit growth in sales and earnings for the current year....
...Leqembi, Biogen’s new Alzheimer’s drug, brought in $19mn in sales in the three months to the end of March, falling below analyst consensus estimates of $30mn as the rollout of the drug faltered....
...An alleged Ponzi scheme run by a Harvard MBA who solicited money from fellow alumni of the prestigious US business school has been shut down by a New York court after collecting more than $2.9mn....
...the drug....
...The company’s work to date has involved analysing thousands of donated human livers to develop an understanding of the causes of disease, and studying whether making changes to RNA — a vital molecule for...
...The shift makes Citadel Securities the latest financial services company to increase its reliance on Big Tech cloud services and is a win for Google as Silicon Valley companies host more business traditionally...
...The EU top court has ruled that the name of the late Colombian drug kingpin Pablo Escobar will not be registered as a trademark in the European Union....
...Emblaveo, marketed in Europe by US pharmaceutical company Pfizer, combines two existing medicines to tackle so-called Gram-negative bacteria that are among the leading drug-resistance threats....
...The company’s immunotherapy drug Imfinzi helped patients with so-called limited stage small cell lung cancer survive for longer....
...Lobritz is co-author with experts from Harvard University of the two papers published in Nature on Wednesday....
...But within a year of the US Food and Drug Administration’s 2021 approval of the weight-loss drugs known as GLP-1 agonists, the threat of them breaking WW’s business model became clear....
...Finding an effective treatment for Alzheimer’s has proved fiendishly difficult for drug companies, and previous regulatory decisions in the field have stirred controversy....
...company in the world....
...The company said the decision was partly driven by huge demand for weight-loss drugs....
...Soaring sales of the products have pushed the companies’ valuations to record highs....
...The deal, which will mark a two-thirds expansion of Citadel’s London office space, comes after Griffin has expressed concern about how hybrid or working-from-home practices can hurt a company’s culture....
...The New York Stock Exchange is polling market participants on the merits of trading stocks around the clock as regulators scrutinise an application for the first 24/7 bourse....
...The firm went as far as asking Engelmayer to close Friday’s hearing to the public and the press, but the judge declined to do so, calling the request “borderline frivolous”....
...insurers to cover the drug....
...Companies linked to the drug lost a combined $40bn in value in days. Pharma groups contest the lab’s results and practices....
...Skydance is offering to buy Redstone’s National Amusements, which controls 77 per cent of Paramount’s voting stock, and later merge with the two companies....
...Privately held Vitol, which employs about 1,800 people, made a record $15.1bn in net profit in 2022 and about $13bn in 2023, making it one of the most profitable companies in the world on a per capita basis...
...The company has genetically validated two other drug targets....
...Scientists said the candidate drug’s discovery, unveiled in a paper last month, could be the basis for research on whether it could be reformulated to target other antibiotic-resistant pathogens....
International Edition